Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Melanoma 8Carcinoma, Non-Small-Cell Lung 7Small Cell Lung Carcinoma 6Squamous Cell Carcinoma of Head and Neck 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Lung Neoplasms 3Diabetes Mellitus, Insulin-Dependent, 12 3Carcinoma, Renal Cell 3Biliary Tract Neoplasms 3Advanced Solid Tumors 3Vulvar Neoplasms 2Vaginal Neoplasms 2Urinary Bladder Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Solid Tumor 1Solid Malignancies 1Peritoneal Neoplasms 1Part A and B: Advanced Solid Malignancies 1Neoplasms 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Dexamethasone 129Lenalidomide 70Cyclophosphamide 70Bortezomib 69Calcium Dobesilate 50fludarabine 44pomalidomide 40daratumumab 37carfilzomib 33fludarabine phosphate 31Melphalan 25dexamethasone acetate 20dexamethasone 21-phosphate 20auricularum 18Filgrastim 18Whole-Body Irradiation 14Biopsy 13isatuximab 12Vorinostat 12Tacrolimus 12Peripheral Blood Stem Cell Transplantation 12Magnetic Resonance Spectroscopy 12Granulocyte Colony-Stimulating Factor 12Specimen Handling 11Sirolimus 11ixazomib 10belantamab mafodotin 10Panobinostat 10Mycophenolic Acid 10Cyclosporine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Multiple Myeloma × tremelimumab × Clear all
NCT02716805 2022-10-12

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Ludwig Institute for Cancer Research

Phase 1 Terminated
6 enrolled 11 charts
Plasma cell

Diabetes Mellitus, Insulin-Dependent, 12, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡